Advanced Therapies Integrates 2024

Bringing together industry leaders to drive the full potential of Advanced Therapies

26th November 2024

EVENT TOPICS:

  • A Digital Revolution & A Person-Centric Approach

Advanced Therapies Integrates is dedicated to uniting industry leaders to drive and realize the full potential of Advanced Therapies and Medicinal Products (ATMPs). The event will focus on the key innovations within complex therapeutics, cell and gene therapies, regenerative medicines and tissue therapies and identify the challenges facing the industry, such as regulatory and commercial barriers to deploying transformational changes.

Uniquely engaging the broadest possible network, including innovators, regulators, supply chain partners, equipment and technology providers, academia, industry associations, and a wide array of government funding bodies and ATMP-focused initiatives, Advanced Therapies Integrates aims to become the leading UK event for translating cutting-edge research and disruptive innovation into widespread adoption of Advanced Therapies, delivering improved patient outcomes and revolutionizing healthcare economics.

KEY SPEAKERS INCLUDE:

Register Now
Rabia Khan

Rabia Khan

Serna Bio
Founder & Chief Executive Officer
Debbie Flanagan

Debbie Flanagan

Gilead Sciences
Director
Katy Newton

Katy Newton

Achilles Therapeutics
Senior Vice President immunology and Process Development
Fredrik Erlandsson

Fredrik Erlandsson

Purespring Therapeutics
Chief Medical Officer
Mustafa Munye

Mustafa Munye

Complement Therapeutics
Vice President Operations
Nicole Mather

Nicole Mather

IBM
Health Data, AI and Life Sciences Lead

AGENDA:

08:30 - 09:30
Registration and Networking
09:30 - 09:40
Welcome & Opening remarks
Matthew Durdy

Matthew Durdy

Cell and Gene Therapy Catapult
Chief Executive Officer

09:45 - 10:05
Fireside chat 1: How do we use information technology to better serve patients in the advanced therapy sector?
Matthew Durdy

Matthew Durdy

Cell and Gene Therapy Catapult
Chief Executive Officer

Nicole Mather

Nicole Mather

IBM
Health Data, AI and Life Sciences Lead

10:10 - 10:30
Fireside chat 2: For the people who need them
A patient group presentation exploring the patient-perspective on the importance of innovations, new gene therapies, and what ATMPs mean for the people, families and communities we’re developing them for.
Nicola Redfern

Nicola Redfern

NJ Redfern Ltd
Consultant

James Kelly

James Kelly

MEF2C Foundation
Chairperson

10:30 - 11:00
Networking Coffee Break

A Digital Revolution & A Person-Centric Approach

11:00 - 11:45

Make them better

Digital technologies offer new opportunities to overcome key challenges in ATMP manufacturing, such as quality control, efficiency and sustainability. How is the UK embracing these opportunities to make ATMPs faster and more efficiently?

Facilitated by

Stephen Ward

Cell and Gene Therapy Catapult
Chief Manufacturing Officer

PANELLISTS

  • Rebecca Street | RoslinCT
  • Katy Newton | Achilles Therapeutics
  • Antoine Espinet | MicrofluidX
  • Edwin Stone | Cellular Origins
  • Kwok Pang | Adthera Bio

11:00 – 11:45

Funding battles

In the current economic environment, both public and private funders are tightening their purse strings. How can we demonstrate the health and economic benefits that would come from a return to previous levels of funding for the ATMP sector?

Facilitated by

Jeanette Evans

Cell and Gene Therapy Catapult
Chief Business Officer

PANELLISTS

  • Karolina Zapadka | Parkwalk Advisors
  • Rabia Khan | Serna Bio
  • Stefanos Theoharis | OneChain Immunotherapeutics
  • Abigail Martin | ImmuONE
  • Simon Chandler | Rinri Therapeutics
  • Sam Goldsmith | Cell and Gene Therapy Catapult

Headline Sponsor:

11:55 - 12:40

Investing in our health

We need to get advanced therapies to the people who need them rapidly and cost-effectively. How can we improve the bench to bedside journey to cut costs and improve efficiencies? How can we ensure the UK sees ATMPs as an investment in our health and economy?

Facilitated by

Nicola Redfern

NJ Redfern Ltd
Consultant

PANELLISTS

  • Eric Halioua | PDC*line Pharma
  • Debbie Flanagan | Gilead Sciences
  • James Rutley | Autolomous
  • William Scott | Newcastle University Medical School
  • Dianne Lee | DLRC
  • Fredrik Erlandsson | Purespring Therapeutics

12:40 – 13:40

Networking Lunch

GOLD AND SILVER SPONSORS:

13:40 - 14:00

Fireside chat 3: From lab to market: The CGT biotech journey

How to succeed in the cell and gene therapy (CGT) space? An insightful session that will delve into the critical factors and strategies for CGT biotech companies to accelerate their journey from lab through clinical development to commercialization.

Facilitated by

Robert Panting

Rentschler Biopharma
General Manager, ATMP

14:05 - 14:50

Hub-ble Bubble

The UK is home to world-class innovation hubs and science parks. How do these hubs support the collaboration and sharing of facilities and expertise required for successful ATMP development?

Facilitated by

James Fry

Mills & Reeve
Partner and Head of Life Sciences

PANELLISTS

  • Michael Baker | FUJIFILM Diosynth Biotechnologies
  • Tom Pike | Stevenage Borough Council
  • Juliana Haggerty | CPI
  • Gillian Molloy | AscellaHealth
  • Marco Delise | Stevenage Bioscience Catalyst

14:50 - 15:05

Refreshment Break

15:05 - 15:50

It’s an upskill battle

Manufacturing ATMPs requires advanced and constantly evolving skills. How can industry and government work together to ensure the UK has the skilled workforce needed for the growth of the ATMP sector?

Facilitated by

Ian Parnham

Cell and Gene Therapy Catapult
Skills Programme Lead

PANELLISTS

  • James Kusena | MFX
  • Mustafa Munye | Complement Therapeutics
  • Ketki Vispute | Autolus
  • Saerah Khan | Rentschler Biopharma
  • Dharmesh Vara | Cytiva
  • Anji Miller | LifeArc

15:50 – 16:50

Networking Drinks Reception

EVENT SPONSORS:

VENUE:

GSK, Stevenage

GSK, Stevenage

GSK, Stevenage

The R&D hub in Stevenage is home to more than 2,500 GSK people focused on discovering and developing new medicines.

The Stevenage Campus base is home to other major organisations including Stevenage Bioscience Catalyst, the Cell and Gene Therapy Manufacturing Catapult, LifeArc and Cytiva alongside a growing cluster of start-up companies.

Options:

By car:
– 20-minute drive to Luton

By train:

-21 minutes from Kings Cross
-35 Minutes from Cambridge

Please click here for directions.

 

Address:

GSK, Gunnels Wood Rd, Stevenage SG1 2NFX
More Details

EVENT SPONSORS: